H22细胞全细胞抗原负载的树突状细胞激活肿瘤浸润性淋巴细胞抗小鼠肝癌的实验  

Anti-mouse Hepatoma Effect of Tumor-infiltrating Lymphocyte Stimulated by DCs Pulsed with H22 Full-cell Antigen

作　　者：冯钟煦[1] 刘剑勇[1] 赵荫农[1] 张志明[1] 张春燕[1] 唐凯[1] 吕丽琼[1] 罗善超[1] 

机构地区：[1]广西医科大学附属肿瘤医院肝胆外科,南宁530021

出　　处：《肿瘤防治研究》2012年第10期1179-1182,共4页Cancer Research on Prevention and Treatment

基　　金：广西医疗卫生重点科研课题资助项目(重200611);广西科学研究与技术开发计划资助项目(桂科攻0719006-2-5);广西科学基金资助项目(桂科自0728196)

摘　　要：目的探讨H22小鼠肝癌细胞(H22细胞)全细胞抗原致敏的树突状细胞激活肿瘤浸润淋巴细胞抗小鼠肝癌细胞活性。方法取得小鼠骨髓细胞并诱导生成树突状细胞,由冻融法制备的H22细胞全细胞抗原致敏,然后用已致敏的树突状细胞激活肿瘤浸润性淋巴细胞,测定致敏前后的DC表面抗原CD11c、CD80、CD86、CD40、MHCⅡ,并评估激活前后的TIL对H22细胞的杀伤活性,同时脾淋巴细胞作为杀伤对照。结果 CD11c阳性细胞中CD80、CD86、CD40、MHCⅡ阳性细胞所占比例在致敏后的DC表现为明显上调。经致敏后成熟DC激活的TIL对H22细胞杀伤活性明显高于未激活的TIL,并高于激活或未激活的小鼠脾脏淋巴细胞。结论在H22细胞全抗原致敏后,小鼠成熟DC中CD80、CD86、CD40、MHCⅡ的表达率明显高于未成熟DC。经H22细胞全细胞抗原致敏的DC能诱导活化TIL,明显提高其在体外对H22细胞的杀伤活性。Objective To study the anti-mouse hepatoma effect of tumor-infiltrating lymphocytes （TILs） stimulated by dendritic cells （DCs） pulsed with the tumor full cell antigen in vitro. Methods DCs were isolated from BALB/c mouse bone marrow and stimulated by granulocyte macrophage colony stimulating factor （GM-CSF）,interieukin-4（IL-4） and H22 full-cell antigen. The maturation surface markers CDSI）, CD86,CD40,MHC II and CD11c were detected by flow cytometry before and after pulsing with whole H22 cells lysates. Then the cytotoxic potency of the TILs was assessed both stimulated and unstimulated, and taking the spleen lymphocytes as control groups. Result The expression of CD80, CD86, CD40, MHC II on the DCs pulsed with H22 full cell lysate is a higher than the DCs after 5d of culture. TILs stimulated by the DCs on mouse hepatoma H22 cells had very special efficient anti tumor effect on the mouse liver cancer H22 in vitro. And the anti-tumor effect of stimulated TIL is higher than the TILs and spleen lymphocytes. Conclusion The results suggest that H22 tumor full cell antigens specific induced tumor-infiltrating lymphocytes have more efficient at killing the H22 cells.

关 键 词：全细胞抗原 树突状细胞 肿瘤浸润性淋巴细胞 抗癌机制 

分 类 号：R73-362[医药卫生—肿瘤]